Clinical Trials Logo

Pleural Sarcomatoid Mesothelioma clinical trials

View clinical trials related to Pleural Sarcomatoid Mesothelioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05647265 Recruiting - Clinical trials for Pleural Biphasic Mesothelioma

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Start date: March 14, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving immunotherapy before surgery may be more effective at controlling disease in patients with sarcomatoid mesothelioma than giving immunotherapy alone.

NCT ID: NCT02399371 Active, not recruiting - Clinical trials for Pleural Malignant Mesothelioma

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Start date: March 31, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum). Monoclonal antibodies, such as pembrolizumab, work by blocking a protein called programmed cell death 1 (PD-1) which may stimulate an immune response and kill tumor cells.